Cutaneous Oncology News

Patients tested with the DecisionDx-Melanoma 31-gene expression profile test experienced 29% lower melanoma-specific mortality and 17% lower overall mortality compared with untested patients, according to a study.

When used in tandem with clinical and dermoscopic examination, optical coherence tomography significantly improved the ability to detect recurrent or residual basal cell carcinomas after topical treatment, according to a study.

The risk for theoretical opioid addiction affected some patients’ choice of pain medications after Mohs micrographic surgery, according to a study.

The sun is finally shining a little brighter this summer, bringing health benefits and also some potential risks this season.

Skin self-examination is a viable secondary prevention method for the early detection of metastatic melanoma and should be promoted to patients, according to an article published in the Journal of the American Academy of Dermatology.

Asian American and Pacific Islander patients are more likely to experience melanoma treatment delays compared with white patients, and these delays are associated with higher mortality rates, according to a study.

Old age and the development of subsequent primary invasive melanoma are risk factors for death following a melanoma in situ diagnosis, according to a study.

The FDA has approved Avita Medical’s premarket approval supplement for the use of its Recell System for the treatment of full-thickness skin defects, according to a press release.

CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.

CHICAGO — Several biomarkers predicted outcomes with adjuvant nivolumab vs. placebo for patients with resected stage IIB or IIC melanoma, according to study results presented at ASCO Annual Meeting.